IL6 and cardiac hypertrophy: Inhibition of Rho leads to a decreased IL-6 secretion, which also contributes to the beneficial effects of statins on cardiac hypertrophy, as IL-6 is associated with reduced left ventricular mass in hypertensive patients (Figure 2) [42,43].